UPDATE ON ANOTHER DRY EYE MEDICATION

Nascent Pharmaceuticals has announced positive results of a Phase IIb clinical trial of iDESTRIN (NP50301), a topical drop for treating dry eye in postmenopausal women.

In patients with moderate-to-severe disease, researchers noted a significant Schirmer's Test improvement of more than 75 percent from baselin, a significant improvement at 12 weeks for superficial punctuate keratopathy and corneal staining.

Significant improvement was achieved for foreign body sensation at four weeks, compared to vehicle in both eyeS. No drug-related serious adverse events were reported.